Medical, Legal, and Regulatory review is not a final hurdle to be cleared once an animation is finished. It is a design condition. The earlier a project is built around approved evidence, intended audience, and review requirements, the less likely it is that essential changes will arrive after the creative work has become expensive to alter.
Define the intended use before writing the script
A film intended for unbranded disease education is not reviewed in the same way as a product-launch asset or a patient-facing resource. Confirm the audience, markets, channels, and claims environment first. This determines the right level of scientific detail, the terminology, and the boundaries of the story.
Create a clear evidence trail
Every material scientific point in the script should be traceable to an agreed source, such as approved product information, client-supplied data, or peer-reviewed literature. The visual treatment needs the same discipline. A diagram, molecular interaction, or disease sequence can communicate an implication even where no spoken claim appears.
Review the storyboard, not just the narration
Animation does more than illustrate the narration. Reviewing only the voiceover can miss how camera direction, colour, scale, labels, and cause-and-effect sequencing shape interpretation. The storyboard is the point at which the scientific, creative, and approval teams should align on what will actually be shown.
Agree how feedback will be handled
Conflicting comments, unclear ownership, and late changes can slow any production. Agree the reviewers, decision makers, review rounds, deadlines, and feedback format before production begins. Consolidated feedback helps the project team distinguish a factual correction from a preference about style.
MLR-ready does not mean visually cautious or uninspiring. It means the creative story is built on an agreed scientific foundation, so the final animation can be both memorable and appropriate for the context in which it will be used.
